Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?

ABSTRACT Although Clinical and Laboratory Standards Institute (CLSI) clinical breakpoints (CBPs) are available for interpreting echinocandin MICs for Candida spp., epidemiologic cutoff values (ECVs) based on collective MIC data from multiple laboratories have not been defined. While collating CLSI caspofungin MICs for 145 to 11,550 Candida isolates from 17 laboratories (Brazil, Canada, Europe, Mexico, Peru, and the United States), we observed an extraordinary amount of modal variability (wide ranges) among laboratories as well as truncated and bimodal MIC distributions. The species-specific modes across different laboratories ranged from 0.016 to 0.5 μg/ml for C. albicans and C. tropicalis, 0.031 to 0.5 μg/ml for C. glabrata, and 0.063 to 1 μg/ml for C. krusei. Variability was also similar among MIC distributions for C. dubliniensis and C. lusitaniae. The exceptions were C. parapsilosis and C. guilliermondii MIC distributions, where most modes were within one 2-fold dilution of each other. These findings were consistent with available data from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (403 to 2,556 MICs) for C. albicans, C. glabrata, C. krusei, and C. tropicalis. Although many factors (caspofungin powder source, stock solution solvent, powder storage time length and temperature, and MIC determination testing parameters) were examined as a potential cause of such unprecedented variability, a single specific cause was not identified. Therefore, it seems highly likely that the use of the CLSI species-specific caspofungin CBPs could lead to reporting an excessive number of wild-type (WT) isolates (e.g., C. glabrata and C. krusei) as either non-WT or resistant isolates. Until this problem is resolved, routine testing or reporting of CLSI caspofungin MICs for Candida is not recommended; micafungin or anidulafungin data could be used instead.

[1]  M. Cuenca‐Estrella,et al.  EUCAST and CLSI: Working Together Towards a Harmonized Method for Antifungal Susceptibility Testing , 2013, Current Fungal Infection Reports.

[2]  M. Arendrup,et al.  EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  M. Arendrup,et al.  EUCAST technical note on anidulafungin. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  Steven D. Brown,et al.  Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[5]  M. Arendrup,et al.  Echinocandin Susceptibility Testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots , 2011, Antimicrobial Agents and Chemotherapy.

[6]  J. Turnidge,et al.  Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp , 2009, Journal of Clinical Microbiology.

[7]  J. Cleary,et al.  Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-d-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint , 2009, Antimicrobial Agents and Chemotherapy.

[8]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Denning,et al.  The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) EUCAST Technical Note on fluconazole. , 2009 .

[10]  M. Arendrup,et al.  Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing , 2008, Antimicrobial Agents and Chemotherapy.

[11]  D. Perlin,et al.  Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints , 2008, Antimicrobial Agents and Chemotherapy.

[12]  D. Kontoyiannis,et al.  Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies , 2008, Antimicrobial Agents and Chemotherapy.

[13]  T. Patterson,et al.  Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection , 2008, Antimicrobial Agents and Chemotherapy.

[14]  F. Dromer,et al.  Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing , 2008, Antimicrobial Agents and Chemotherapy.

[15]  H. Schønheyder,et al.  Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  J. Cleary,et al.  Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment , 2008, Antimicrobial Agents and Chemotherapy.

[17]  Steven D. Brown,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Third informational supplement , 2008 .

[18]  K. Marr,et al.  Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients , 2007, British journal of haematology.

[19]  G Kahlmeter,et al.  Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  Patrick R. Murray,et al.  Candida, Cryptococcus, and other yeasts of medical importance. , 2006 .

[21]  J. Perfect,et al.  Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species , 2004, Journal of Clinical Microbiology.

[22]  P. Wayne Reference method for broth dilution antifungal susceptibility testing of yeasts, Approved standard-second edition , 2002 .